Hy's law

Jump to navigation Jump to search

WikiDoc Resources for Hy's law

Articles

Most recent articles on Hy's law

Most cited articles on Hy's law

Review articles on Hy's law

Articles on Hy's law in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hy's law

Images of Hy's law

Photos of Hy's law

Podcasts & MP3s on Hy's law

Videos on Hy's law

Evidence Based Medicine

Cochrane Collaboration on Hy's law

Bandolier on Hy's law

TRIP on Hy's law

Clinical Trials

Ongoing Trials on Hy's law at Clinical Trials.gov

Trial results on Hy's law

Clinical Trials on Hy's law at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hy's law

NICE Guidance on Hy's law

NHS PRODIGY Guidance

FDA on Hy's law

CDC on Hy's law

Books

Books on Hy's law

News

Hy's law in the news

Be alerted to news on Hy's law

News trends on Hy's law

Commentary

Blogs on Hy's law

Definitions

Definitions of Hy's law

Patient Resources / Community

Patient resources on Hy's law

Discussion groups on Hy's law

Patient Handouts on Hy's law

Directions to Hospitals Treating Hy's law

Risk calculators and risk factors for Hy's law

Healthcare Provider Resources

Symptoms of Hy's law

Causes & Risk Factors for Hy's law

Diagnostic studies for Hy's law

Treatment of Hy's law

Continuing Medical Education (CME)

CME Programs on Hy's law

International

Hy's law en Espanol

Hy's law en Francais

Business

Hy's law in the Marketplace

Patents on Hy's law

Experimental / Informatics

List of terms related to Hy's law

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Hy's law is a prognostic indicator that a pure drug-induced liver injury (DILI) leading to jaundice, without a hepatic transplant, has a case fatality rate of 10% to 50%. The law is based on observations by Hy Zimmerman, a major scholar of drug-induced liver injury.

Hy’s Law cases have the following three components (http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0396-gdl0001.pdf):

  1. The drug causes hepatocellular injury, generally shown by more frequent 3-fold or greater elevations above the ULN of ALT or AST than the (nonhepatotoxic) control agent or placebo.
  2. Among subjects showing such AT elevations, often with ATs much greater than 3xULN, some subjects also show elevation of serum TBL to >2xULN, without initial findings of cholestasis (serum alkaline phosphatase (ALP) activity >2xULN).
  3. No other reason can be found to explain the combination of increased AT and TBL, such as viral hepatitis A, B, or C, preexisting or acute liver disease, or another drug capable of causing the observed injury. [1][2]

References

Template:WikiDoc Sources